EGFR and non-small cell lung carcinoma: A retrospective analysis of the phase III FLEX study of chemotherapy in combination with cetuximab in patients with EGFR‐expressing advanced NSCLC, showed 35% with negative PTEN expression.44 The presence of PTEN expression is potentially correlated with improved survival.